• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

用于HIV-1感染的树突状细胞免疫疗法的进展。

Advances in dendritic cell immunotherapies for HIV-1 infection.

作者信息

Miller Elizabeth, Bhardwaj Nina

机构信息

Mount Sinai School of Medicine, Hess Center for Science and Medicine, Division of Infectious Diseases , 1470 Madison Avenue, New York, NY 10029 , USA.

出版信息

Expert Opin Biol Ther. 2014 Nov;14(11):1545-9. doi: 10.1517/14712598.2014.950652. Epub 2014 Aug 21.

DOI:10.1517/14712598.2014.950652
PMID:25143151
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6043898/
Abstract

Augmentation of adaptive immunity via HIV therapeutic vaccination may be a key component of curative strategies. Adoptive dendritic cell (DC) immunotherapies may prove useful in enhancing the success of these approaches by circumventing certain defects in DC function during HIV infection. Thus far, DC immunotherapies that utilize autologous, inactivated virus as an immunogen have provided the most promising results however, are beset with practical constraints. Consequently, alternative forms of immunogens are under investigation, with an emphasis on RNA-based approaches. Here we review the data from DC immunotherapy trials for HIV infection and discuss challenges and future directions in the field.

摘要

通过HIV治疗性疫苗接种增强适应性免疫可能是治愈策略的关键组成部分。过继性树突状细胞（DC）免疫疗法可能通过规避HIV感染期间DC功能的某些缺陷，有助于提高这些方法的成功率。迄今为止，利用自体灭活病毒作为免疫原的DC免疫疗法已取得了最有前景的结果，然而，该疗法存在实际限制。因此，正在研究替代形式的免疫原，重点是基于RNA的方法。在此，我们综述了HIV感染DC免疫疗法试验的数据，并讨论了该领域的挑战和未来方向。

相似文献

1
Advances in dendritic cell immunotherapies for HIV-1 infection.用于HIV-1感染的树突状细胞免疫疗法的进展。
Expert Opin Biol Ther. 2014 Nov;14(11):1545-9. doi: 10.1517/14712598.2014.950652. Epub 2014 Aug 21.
2
Autologous aldrithiol-2-inactivated HIV-1 combined with polyinosinic-polycytidylic acid-poly-L-lysine carboxymethylcellulose as a vaccine platform for therapeutic dendritic cell immunotherapy.自体二硫苏糖醇-2 灭活 HIV-1 联合聚肌苷酸-聚胞苷酸-聚赖氨酸羧甲基纤维素作为治疗性树突状细胞免疫治疗的疫苗平台。
Vaccine. 2015 Jan 3;33(2):388-95. doi: 10.1016/j.vaccine.2014.10.054. Epub 2014 Nov 15.
3
The Evolution of Dendritic Cell Immunotherapy against HIV-1 Infection: Improvements and Outlook.树突状细胞免疫疗法对抗 HIV-1 感染的演进：改进与展望。
J Immunol Res. 2020 May 25;2020:9470102. doi: 10.1155/2020/9470102. eCollection 2020.
4
Dendritic cell-based human immunodeficiency virus vaccine.基于树突状细胞的人类免疫缺陷病毒疫苗。
J Intern Med. 2009 Jan;265(1):138-58. doi: 10.1111/j.1365-2796.2008.02047.x.
5
Challenges in dendritic cells-based therapeutic vaccination in HIV-1 infection Workshop in dendritic cell-based vaccine clinical trials in HIV-1.在 HIV-1 感染中基于树突状细胞的治疗性疫苗接种的挑战 HIV-1 树突状细胞疫苗临床试验研讨会
Vaccine. 2011 Sep 2;29(38):6454-63. doi: 10.1016/j.vaccine.2011.07.043. Epub 2011 Jul 23.
6
HIV-1 Reservoir Dynamics after Vaccination and Antiretroviral Therapy Interruption Are Associated with Dendritic Cell Vaccine-Induced T Cell Responses.接种疫苗和中断抗逆转录病毒治疗后的HIV-1储存库动态与树突状细胞疫苗诱导的T细胞反应相关。
J Virol. 2015 Sep;89(18):9189-99. doi: 10.1128/JVI.01062-15. Epub 2015 Jun 24.
7
Treating HIV-1 infection with dendritic cells.用树突状细胞治疗HIV-1感染。
Curr Opin Mol Ther. 2007 Aug;9(4):353-63.
8
DC immunotherapy in HIV-1 infection induces a major blood transcriptome shift.HIV-1感染中的树突状细胞免疫疗法可引起血液转录组的重大转变。
Vaccine. 2015 Jun 9;33(25):2922-9. doi: 10.1016/j.vaccine.2015.04.047. Epub 2015 Apr 24.
9
Dendrimers as nonviral vectors in dendritic cell-based immunotherapies against human immunodeficiency virus: steps toward their clinical evaluation.树枝状大分子作为基于树突状细胞的抗人类免疫缺陷病毒免疫疗法中的非病毒载体：迈向其临床评估的步骤。
Nanomedicine (Lond). 2014 Dec;9(17):2683-702. doi: 10.2217/nnm.14.172.
10
Arcelis AGS-004 dendritic cell-based immunotherapy for HIV infection.基于 Arcelis AGS-004 树突状细胞的免疫疗法治疗 HIV 感染。
Immunotherapy. 2010 Jul;2(4):467-76. doi: 10.2217/imt.10.28.

引用本文的文献

1
Dendritic Cells in HIV/SIV Prophylactic and Therapeutic Vaccination.HIV/SIV预防性和治疗性疫苗接种中的树突状细胞
Viruses. 2019 Dec 24;12(1):24. doi: 10.3390/v12010024.
2
Current Advances in Virus-Like Particles as a Vaccination Approach against HIV Infection.病毒样颗粒作为一种预防 HIV 感染的疫苗接种方法的最新进展。
Vaccines (Basel). 2016 Jan 22;4(1):2. doi: 10.3390/vaccines4010002.
3
Immunization of HIV-1-Infected Persons With Autologous Dendritic Cells Transfected With mRNA Encoding HIV-1 Gag and Nef: Results of a Randomized, Placebo-Controlled Clinical Trial.用编码HIV-1 Gag和Nef的mRNA转染的自体树突状细胞对HIV-1感染者进行免疫：一项随机、安慰剂对照临床试验的结果。
J Acquir Immune Defic Syndr. 2016 Mar 1;71(3):246-53. doi: 10.1097/QAI.0000000000000852.
4
DNA is an efficient booster of dendritic cell-based vaccine.DNA是基于树突状细胞疫苗的有效增强剂。
Hum Vaccin Immunother. 2015;11(8):1927-35. doi: 10.1080/21645515.2015.1020265.

本文引用的文献

1
Immunogenicity of AGS-004 Dendritic Cell Therapy in Patients Treated During Acute HIV Infection.急性HIV感染期接受治疗的患者中AGS-004树突状细胞疗法的免疫原性
AIDS Res Hum Retroviruses. 2018 Jan;34(1):111-122. doi: 10.1089/aid.2017.0071. Epub 2017 Jun 21.
2
Conserved immunogens in prime-boost strategies for the next-generation HIV-1 vaccines.下一代HIV-1疫苗初免-加强策略中的保守免疫原。
Expert Opin Biol Ther. 2014 May;14(5):601-16. doi: 10.1517/14712598.2014.885946. Epub 2014 Feb 3.
3
Unravelling the mechanisms of durable control of HIV-1.解析 HIV-1 持久控制的机制。
Nat Rev Immunol. 2013 Jul;13(7):487-98. doi: 10.1038/nri3478.
4
Dendritic cell dysregulation during HIV-1 infection.HIV-1 感染期间树突状细胞的失调。
Immunol Rev. 2013 Jul;254(1):170-89. doi: 10.1111/imr.12082.
5
Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study.早期启动抗逆转录病毒治疗中断后实现长期病毒学缓解的治疗后HIV-1控制者：ANRS VISCONTI研究
PLoS Pathog. 2013 Mar;9(3):e1003211. doi: 10.1371/journal.ppat.1003211. Epub 2013 Mar 14.
6
A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication.一种基于树突状细胞的疫苗能引发与控制 HIV-1 复制相关的 T 细胞应答。
Sci Transl Med. 2013 Jan 2;5(166):166ra2. doi: 10.1126/scitranslmed.3004682.
7
Can immunotherapy be useful as a "functional cure" for infection with Human Immunodeficiency Virus-1?免疫疗法可否作为人类免疫缺陷病毒 1 感染的“功能性治愈”手段？
Retrovirology. 2012 Sep 7;9:72. doi: 10.1186/1742-4690-9-72.
8
Plasma factors during chronic HIV-1 infection impair IL-12 secretion by myeloid dendritic cells via a virus-independent pathway.慢性 HIV-1 感染期间的血浆因子通过非病毒依赖途径损害髓样树突状细胞分泌 IL-12。
J Acquir Immune Defic Syndr. 2012 Dec 15;61(5):535-44. doi: 10.1097/QAI.0b013e31826afbce.
9
HIV controllers maintain a population of highly efficient Th1 effector cells in contrast to patients treated in the long term.HIV 控制器与长期接受治疗的患者不同，其体内维持着一群高效的 Th1 效应细胞。
J Virol. 2012 Oct;86(19):10661-74. doi: 10.1128/JVI.00056-12. Epub 2012 Jul 25.
10
A phase I/IIa immunotherapy trial of HIV-1-infected patients with Tat, Rev and Nef expressing dendritic cells followed by treatment interruption.一项Ⅰ/Ⅱa 期免疫疗法临床试验，旨在研究表达 Tat、Rev 和 Nef 的树突状细胞治疗 HIV-1 感染患者，随后进行治疗中断。
Clin Immunol. 2012 Mar;142(3):252-68. doi: 10.1016/j.clim.2011.10.010. Epub 2011 Nov 16.